The hepatocellular carcinoma (HCC) market in China is poised to experience substantial market growth. Availability of systemic targeted drugs is limited, with only three agents beyond surgery or chemotherapy available. However, the pipeline of emerging therapies is promising, with a large number of treatments being developed both within and outside China. We anticipate a significant growth in the HCC market of China over the next ten years, driven particularly by the launch and uptake of immune checkpoint inhibitors—Tecentriq, Opdivo, and Keytruda. Additionally, following the recent reforms in China’s regulatory and reimbursement landscape, manufacturers—both domestic and multinational—will be increasingly incentivized to enter the growing HCC market over the coming years.
- How large are the drug-treatable HCC populations and how will the drug-treatment rates change over time?
- What is the current state of the China HCC market? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled? What are the current opportunities in the HCC market?
- What are the key market access considerations of the most promising pipeline products? What sales/uptake could they secure in HCC?
- What are key drivers and constraints in the China HCC market, and how will the market evolve over the forecast period?
- How do national and provincial policies affect access to oncology therapies in China?
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading medical oncologists Supported by survey data collected for this and other DRG research epidemiology Diagnosed incidence of HCC by disease stage. Clinically and market relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient shares of key HCC regimens through 2028, based on primary and secondary market research to formulate bottom-up assumptions
Phase III: 15+ drugs. Phase II: 10+ drugs. Coverage of select early-phase products.